

...F...  
...L... ,F P...  
...P... C... E... O... F... P...

...P... C... E... O... F... P...

# Abstract

## The 2016 Corporate Social Responsibility (CSR) Report Published by SAGAL Finance Practice Co., Ltd.

The 2016 Corporate Social Responsibility (CSR) Report published by SAGAL Finance Practice Co., Ltd. (SAGAL) is a comprehensive document that details the company's commitment to social responsibility and its various initiatives. The report is structured into several key sections:

- Introduction:** Provides an overview of the report's purpose and the company's CSR strategy.
- Materiality:** Discusses the identification of material issues and the company's approach to addressing them.
- Materiality Matrix:** A tool used to assess the significance of different CSR issues.
- Materiality Assessment:** Details the process of evaluating the impact of the company's activities on stakeholders.
- Materiality Results:** Presents the findings of the assessment, highlighting the most significant areas of focus.
- Materiality Initiatives:** Describes the specific programs and actions implemented to address the identified material issues.
- Materiality Performance:** Shows the results and achievements of the initiatives, supported by data and metrics.
- Materiality Review:** Reflects on the progress made and identifies areas for future improvement.
- Materiality Outlook:** Provides a forward-looking perspective on the company's CSR goals and commitments.

The report is designed to be transparent and accessible, providing stakeholders with a clear understanding of the company's CSR performance and its commitment to creating long-term value for all stakeholders.



The 2016 Corporate Social Responsibility (CSR) Report published by SAGAL Finance Practice Co., Ltd. (SAGAL) is a comprehensive document that details the company's commitment to social responsibility and its various initiatives. The report is structured into several key sections:

- Introduction:** Provides an overview of the report's purpose and the company's CSR strategy.
- Materiality:** Discusses the identification of material issues and the company's approach to addressing them.
- Materiality Matrix:** A tool used to assess the significance of different CSR issues.
- Materiality Assessment:** Details the process of evaluating the impact of the company's activities on stakeholders.
- Materiality Results:** Presents the findings of the assessment, highlighting the most significant areas of focus.
- Materiality Initiatives:** Describes the specific programs and actions implemented to address the identified material issues.
- Materiality Performance:** Shows the results and achievements of the initiatives, supported by data and metrics.
- Materiality Review:** Reflects on the progress made and identifies areas for future improvement.
- Materiality Outlook:** Provides a forward-looking perspective on the company's CSR goals and commitments.

The report is designed to be transparent and accessible, providing stakeholders with a clear understanding of the company's CSR performance and its commitment to creating long-term value for all stakeholders.

# CONTENTS

04 A R

14 A



42 H



90 C



112 P I S I

115 F F

116 T C N

121 T P E

06 H 2016

32 E



56 I



102 C



122 G O C S R  
P (GB36002)

131 G R I G4I I

140 A S SGS

# Highlights of 2016

July


August

September

In July, we announced that we had received FDA approval for our first generic drug, **gabapentin**. This is a significant milestone for our company as it marks our first generic drug approval. We also received FDA approval for our first generic drug, **gabapentin**, which is a significant milestone for our company as it marks our first generic drug approval. We also received FDA approval for our first generic drug, **gabapentin**, which is a significant milestone for our company as it marks our first generic drug approval.

In August, we announced that we had received FDA approval for our first generic drug, **gabapentin**. This is a significant milestone for our company as it marks our first generic drug approval. We also received FDA approval for our first generic drug, **gabapentin**, which is a significant milestone for our company as it marks our first generic drug approval.

In September, we announced that we had received FDA approval for our first generic drug, **gabapentin**. This is a significant milestone for our company as it marks our first generic drug approval. We also received FDA approval for our first generic drug, **gabapentin**, which is a significant milestone for our company as it marks our first generic drug approval.



December

Designed Receptor R&D and  
 Initial Phase I R&D  
 Clinical Studies

International and Foreign  
 Regulatory Affairs  
 YAPharma launched in the US  
 market

Greatly exceeded expectations  
 Refinancing and debt  
 restructuring, completion of  
 Huihua Hospital Management Group  
 Co., Ltd.

As of 2016, F. Hoffmann-L. A. HL 07  
 M. C., T. S.  
 HER2.  
 T.  
 I.  
 H. A. P.  
 PA-824,  
 S.

I. S. P.  
 F. P.  
 S.  
 S.  
 T.  
 C.  
 P. S.  
 C. I.  
 C.  
 T.  
 P.

M. G., F. P.  
 G. T. I. G.  
 M. G.  
 A. H. H.  
 M. G. C., L.  
 10 D. T.  
 C. I.  
 C. I.  
 C. I.


# Rewards and Recognitions



## Industry Ranking Category

- July • **Top 100 Pharmaceutical Industry Enterprises of China**  
China National Pharmaceutical Industry Information Center of Ministry of Industry and Information
- September • **Ranked 3rd among the Top 100 Strengths of Pharmaceutical Research and Development in China, ranked 2nd among the Strengths of Biopharmaceutical Research and Development in China**  
YAOZH.COM
- November • **Ranked 14th among the Top 100 Companies in China Pharmaceutical Industry**  
CFDA South Medicine Economic Research Institute, Medicine Economic News
- November • **Top Ten Pharmaceutical Industry Enterprise Group of China**  
China Pharmaceutical Industry Association, China Association of Pharmaceutical Commerce
- November • **Top 100 Future Enterprises in China**  
ACCA (The Association of Chartered Certified Accountants)
- November • **Most Innovative Multinational Companies**  
Bioclub





### Marketing & Sales Category

### Customer Service Category

- January

Best Investor Relations Award  
Awarding Institution: China Financial Market Financial Magazine
- June

The Best Overseas Medical Investment Enterprises  
Awarding Institution: China Chamber of Commerce for Import and Export of Medicines and Health Products
- October

Top 20 Most Competitive Listed Pharmaceutical Companies in China, Top 10 Listed Pharmaceutical Companies with the Highest Investment Value  
Awarding Institution: China Pharmaceutical Enterprise Management Association
- November

Best Listed Companies in Pharmaceutical Industry  
Awarding Institution: Value Line, China Economic Net, China reform Daily

- January

The Best Social Responsibility Brand  
Awarding Institution: Media of the Fifth Charity Festival
- July

Responsibility Innovation Best Case Award for the Year  
Awarding Institution: Jiefang Daily (Shanghai Observer), Shanghai Daily, etc.
- December

Corporate Social Responsibility of Listed Companies ranked 2nd in CSR Development Index and ranked 1st in Report Appraisal Results  
Awarding Institution: SSRB, Shanghai Stock Exchange, Xinhuanet, Shanghai Association of Listed Companies, etc.
- December


Golden Bee Excellent CSR Report 2016 Leading Enterprise Award  
Awarding Institution: MOC China WTO Tribune



**M**




F P C  
1994 S S E ( :  
600196-SH) A 1998 M B S E  
H K L ( :02196-HK) O 2012. F  
F P G  
C  
T G  
R&D,  
A F  
P G R&D  
S C T S F  
S T G R&D  
I C F P G  
G C F P G  
S C F P G  
F P G  
P G  
F P G



为爱飞

向上海市福利





# Grand Strategy

**F P G** - The firm's overall strategy, which is the result of the combination of the firm's business strategy and its financial strategy.

**F** - Financial strategy, which is the firm's strategy for raising capital and managing its financial resources.




**R&D** - Research and Development, which is the firm's strategy for developing new products and technologies.

**S** - Business strategy, which is the firm's strategy for competing in its market.

**L** - Legal strategy, which is the firm's strategy for managing its legal risks.

**M&A** - Mergers and Acquisitions, which is the firm's strategy for growing through the acquisition of other companies.


## Strategic

-  **S G** - Strategic goals, which are the firm's long-term objectives.
-  **M G** - Marketing goals, which are the firm's objectives for its marketing activities.
-  **D** - Development goals, which are the firm's objectives for its product and service development.


## Strategic Decision

-  **S G** - Strategic goals, which are the firm's long-term objectives.
-  **M G** - Marketing goals, which are the firm's objectives for its marketing activities.
-  **B** - Business strategy, which is the firm's strategy for competing in its market.









# Combating Childhood Malnutrition

Learn more about our commitment to fighting childhood malnutrition. For more information, visit [www.fpg.com/childhoodmalnutrition](#).

For more information, visit [www.fpg.com/childhoodmalnutrition](#).

# Corporate Management

F P G  
M M C C M P D C M M D C T M S  
M C S F P I T  
F P  
G  
T C  
D S S P C D B L S D T M B  
M D S D P F D D C I D T 22 R&D C EHS  
D D C B P M D D B P A D D H M R  
D D I R P C D D I A B D S  
D C I C D P C (R ) I D M M M  
C /I C C /F H I C M D M S D  
D I 2016 C M T B D D T  
O M D C M D D G P A  
C  
T  
I B M D C C I M C C O P M C C  
C M C C C C R C C B P M C  
EHS M C S C I 2016 C O  
M C I M C C O

# Corporate Governance

I C  
C R CSRC L C R L S SSE, A L C C G C L  
L R S E  
A C T  
C C T  
T B D C S  
A B D T C A  
B D A A

A :T C

A M I D L C CSRC, G M


S E I D L C SSE, G A S

R I D D L C SSE, R A S

M E S E A I S R M C S I

D I I A S M E A R I

C S R R S A R I C



27

## Leadership and Governance

In 2016, F. P. R. G. A.-C. F. P. OA  
42  
A.-C. S. D. 23  
C.

## Achievements and Results

In 2016, G. T. G.  
T.

## Digital Transformation

In 2016, F. P. I. F. P. IT. S. B. P.  
I. S. M.  
G. 2016.

## The Commitment to Safety

T. F.

# Maer a A a

F P

I 2016, F P

C ,EHS,

M CSR F P 2016

(CSR )

( )

C

C

( )

( )

C

C

**Ide ca f e**

S 30

**F a f e ba**

**I e e a d e c a g e**

C 200

**A e e a d a a f e**

**S e e g a d a e e**


E

**S e e g f a e r a e**

**A r a a d c r a**

C

**R e d g a e r a e**




- 1 P
- 2 R
- 3 O
- 4 Q
- 5 S
- 6 R
- 7 C
- 8 C
- 9 A -C
- 10 I
- 11 Q
- 12 T
- 13 P
- 14 I
- 15 H
- 16 M
- 17 C
- 18 C
- 19 G
- 20 G
- 21 C
- 22 R
- 23 P
- 24
- 25 C
- 26 C
- 27 T
- 28 A
- 29 I
- 30 C
- 31 C
- 32 D

## State of CSR

F P ... E  
 F P ... G  
 CSR ...  
 F P ... I 2016, F P ...  
 CSR ... A, GE L, S C P ...  
 I J 2016, 12 I F C S R C TOT  
 M C PRC G B 2030 S R A ... F  
 P S G C C S P G, I (C ), D P C

## Partnership & External CSR G de e f P ar ace ca

O 10 M, C P E A C P I A C  
 A M D I C P C A C A C  
 T C M C N P M A  
 CSR P G P E C B T  
 CSR  
 F P CSR P G P E C O 3 A F  
 P CSR C EHS F P F P F  
 CSR



## CSR Management










F P G CSR  
 CSR  
**CSR P**  
 F P G T G  
 G F P G



CSR M P



# S a e der

S	E	F	P	R	F	P
 <p>S</p>	<p>S</p> <p>P</p> <p>O</p>			<p>L</p> <p>T</p> <p>E</p> <p>C</p>		
 <p>C</p>	<p>P</p> <p>P</p> <p>P</p>			<p>P</p> <p>M</p> <p>C</p> <p>E</p> <p>E</p> <p>P</p>		
 <p>M</p>	<p>M</p> <p>S</p>			<p>E</p> <p>C</p> <p>E</p> <p>T</p>		
 <p>E</p>	<p>P</p> <p>P</p> <p>C</p>			<p>E</p> <p>E</p> <p>E</p> <p>O</p> <p>S</p> <p>S</p>		
 <p>S</p>	<p>A</p> <p>J</p>			<p>E</p> <p>C</p> <p>G</p>		
 <p>G</p>	<p>F</p> <p>L</p> <p>F</p>			<p>O</p> <p>C</p> <p>P</p> <p>A</p> <p>P</p>		
 <p>C</p>	<p>C</p> <p>S</p> <p>C</p>			<p>A</p> <p>P</p> <p>A</p>		
 <p>P</p>	<p>T</p> <p>C</p>			<p>O</p> <p>C</p>		
 <p>P</p>	<p>F</p> <p>S</p>			<p>C</p> <p>C</p> <p>P</p>		



## Ser

I 2016, F P P B S P  
T M S F P (G ) C , L T L  
P M A I S F P (G ) C , L  
T ;

F P ;

A F P G

## Peer Interact

F P I 2016, F P ;

I J , F P CIMC, M G  
2016 A M C E A -F A ;

I S F P C C  
B  
I N A ;

I O , F P 2016 F P B I  
C I S  
C F P F P ;

I D 9 G B I F CSR R C 12  
I F S R C TOT , F P  
CSR

## Partner and board

F P I 2016,  
P F

F P P  
I S P F P S S C  
S J C  
P T P F P  
P S P D , P S  
P T

## Community, -g er e sa rga a

I 2016, F P G 35 ;

I 2016, G 100 ;

T 90 ;



C 35



T 90

**T e P b c**

F P ;

T F P C F P ( L I ),

I 2016, F P ;

F P C G

F P G F

P B P R D I 2016, F P F P I S , I

G ;

F P I 2016, 250,471

P I S P A G

**Rea e g e e**

F P 2016 P C L O D C C B 2016 M S C I D C C 100 C 30

F P Q D M C C 2016 30

P 20 I

P F P A M R P A L

T P I C M I I 13 F - P

S CPPCC S CPPCC

P S D P H I

T D R D D CFDA C T S C T M S C B

A T R E G L B B - I , R&D P H S F P I


S ;

H P S T P S C T H P I C A A


N - F S T A C A A

T S B

G H P S B C G H












# ca I dca fF , P ar aGr ,



# fr b e eg e



# re eac a dde e





## Operating Results



2016, FY		2015, FY	
Operating Profit	Operating Profit Margin	Operating Profit	Operating Profit Margin
RMB14,628.82	16.02%	RMB10,259.54	14.83%
RMB14,628.82 (2016, FY) vs RMB10,259.54 (2015, FY)			
RMB2,805.84 (2016, H1) vs RMB3,571.55 (2015, H1)			
RMB2,092.78 (2016, H1) vs RMB2,092.78 (2015, H1)			
5.92%, 14.05% (2016, H1) vs 26.36% (2015, H1)			

## Production and Sales

2016, FY		2015, FY	
Production	Sales	Production	Sales
RMB14,628.82	RMB10,259.54	RMB10,259.54	RMB10,259.54
RMB2,805.84 (2016, H1) vs RMB3,571.55 (2015, H1)			
RMB2,092.78 (2016, H1) vs RMB2,092.78 (2015, H1)			
5.92%, 14.05% (2016, H1) vs 26.36% (2015, H1)			

## R&D Performance

R&D Investment of Fosun Pharma Group for 2012-2016 (RMB1,000,000)



In 2016, R&D investment increased to RMB1,106 million (an increase of 33.23% compared to 2015). R&D investment as a percentage of operating income increased to 6.67% (up from 5.6% in 2015).

## R&D Investment

Year	Total R&D Investment (RMB)	Operating Income (RMB)	R&D Investment as a Percentage of Operating Income
2016	RMB1,106	RMB16,567	6.67%
2015	RMB715	RMB12,640	5.6%

## R&D Pipeline

Year	Phase 1	Phase 2	Phase 3	Phase 4	Phase 5	Phase 6	Phase 7	Phase 8	Phase 9	Phase 10
2016	173	10	1	1	1	1	1	1	1	1
2015	173	10	1	1	1	1	1	1	1	1

## Patent Applications

Year	Patent Applications	Patent Applications
2016	103	21
2015	103	21

## Patent Applications and Factoring

Year	Patent Applications	Factoring
2016	103	14.83%
2015	103	14.83%

T A M P

T	A	M	P
T	A	P	INN
		A	R P G F B
		S L	P I F II
M		S P	G T F II
		B	R E H I F
		L T	F F
		N/A	C F
		A	M C A T
		D E	A I D E T
		K	D T
C		B T	H I T
		B T	T F
		B	P H
		M	C F
B		A D J	D I C B T ( )
		Q	O T F T
A		ARTES NPL S	A P M M
		ARTES N	
		C C	C S T
		S D L K	I
		N N K	E P I H R T F
A		N/A	R I
		Q S S L	P S S F
		E B	

# Healthcare Service

I 2016, RMB1,677.56, 21.67% 2015. I 2016, G

I 2016, P II Q Q H S H G H G I ( B H ) C H G T G C M G G S F G L T B M J Q C O20 A H G H H ) C H J, C H G 3,018. F G F H C (CHD ). I 2016, F H B S T F H Q S P F H G

# Medical Device and Medical Drug

I 2016, G T RMB2,663.91, 18.17% 2015. I 2016, A L C I I 2016, A L RMB786.21, 14.19% 2015. I R&D I 2016, A L 6 E CE 2 S.FDA 2016, G S G I 2016, G CML 2016, D 2016, I 19,000 2016, M C H K 54% 2015. M C I S I S 0.05 ( T1 0 ( ) 3 ) 5 . 6 ( ) 0 . 6 ( 4 ( ) 0.5 7.6 ( ) 10.0.050.011 ) 0.6 ( ) 0 . 4.1 ( 0.4 ( ) 0.5 ) 0.011 50.5 ( ML ( ( 6 ( ) T 0.9 ( ) ) 4.019- ( . 9 ( D ) 34 ( ) ) 0 ML ( ( ) 4 ( ) 6 . . 004 T 0 ( ) 6 ( 8618611 ) 0.05 ( ) -25

# Percentage of Cash Dividends Paid

Year	2016	2015
Percentage of Cash Dividends Paid	12.99%	23.20%
Number of Shares	31	14,231
Value of Dividends Paid (RMB)	4,647	10,239
Value of Cash Dividends Paid (RMB)	258,388	6,892
Value of Other Dividends Paid (RMB)	246,459	10,239
Percentage of Other Dividends Paid	17.29%	13.34%

# Great for a Growing M&A and Regra

In 2016, G... G... G...

A  
(C

F P G

L F P (RMB10,000)

O \* T

2016	7,873	2,001	7,614	841	225,356	
2015	6,345	1,519	4,962	3	200,597	
2014	20,678	4,759	1,408	4,850	285	163,190

\*N


## Walaupun Gerak Halus

...G...H...T  
J...2016, ...C...T  
...C...T  
...C...F

## Yogyakarta Medical Education Management Council

...G...M...I...M  
C...L...  
...F...H...I...N.1  
P...N.1P...C...F...P...  
T...  
...A...C...H...  
...B...H...-4...12...4







爱满新世界

OF 9S ,S O C F ,F  
F S N :L L F N A  
S S C R C  
M S C F  
I A .T M.L





## E a ce a a a age e



I 2016, O P Q A  
I C F P 13  
14

## I e e a e C y c

I	2015	2016
D S A	77	58
N	358	401

F P G  
A  
B  
C  
D  
E  
F  
G  
H  
I  
J  
K  
L  
M  
N  
O  
P  
Q  
R  
S  
T  
U  
V  
W  
X  
Y  
Z

## I e e Q a S e C e r c a

13  
API  
ce f ed b  
cGMC

C SA, E, M. 13 API H J, H B GMC FDA  
G P 1  
2 API (5 API),  
1 H C  
HO-PQ P  
FDA SA.



## Pa a e a a a g

I 2016, F P G  
A  
B  
C  
D  
E  
F  
G  
H  
I  
J  
K  
L  
M  
N  
O  
P  
Q  
R  
S  
T  
U  
V  
W  
X  
Y  
Z

## I e c e e e c e

## I e e a c a e e e e a r a

P  
A  
B  
C  
D  
E  
F  
G  
H  
I  
J  
K  
L  
M  
N  
O  
P  
Q  
R  
S  
T  
U  
V  
W  
X  
Y  
Z

I 2016, C H  
E H I M  
S (NHFP C H N )

# Service framework

P F P S A 2016, F P R  
 A T G EHS  
 F P M  
 R F P G  
 C T C  
 C T C  
 C  
 F P G  
 R&D,  
 M  
 R&D,  
 H F P G G M  
 I 2016,  
 3,018


## Compliance

I 2015,  
 G P D M Q M F E L P Q  
 C P P M  
 I 2016, G  
 B GMP GMP GMP  
 T 2016  
 I 2016, O M D G O P Q  
 A I C F P 13  
 I 2016, 14  
 P B E G P  
 T  
 T O M D  
 CAPA  
 F GMP, GMP, G  
 G OOS  
 F P  
 I 2016, G 58  
 A  
 2010 GMP GMP T  
 401  
 I 2016,  
 M F P G  
 T M I S M R



M

3,018



I 2016, O A  
 P Q A  
 I C F  
 P 13 .14



100%

401 58

.T  
 .E  
 I 2016, ISO13485  
 CE  
 .A  
 F P  
 .A

I	S	P	S	F	P	G	D	F	A	R
	S									
	H	P			0				16	P
	A	P			2				14	P
		A			3				0	P
		F			7				5	P
	H	P			5				33	P
		B			1				22	P
		T			2				15	P
		P			0				39	P
	C	B			5				1	P
		J			4				0	P
		S			3				1	P
	S	S			1				0	P
	D	P			2				13	P
	E	P			2				60	P
	G	P			9				39	P
		P			5				136	P
	C	P			2				7	P
	H	P			0				0	P
	R	P			4				0	P
	S	H			2				0	P
		T			58				401	P

S	C	R	I	M	D	S	F	P	G
S		D		A			S	A	R
P	E	F	2016	.S.FDA			( I), ( II), ( III), ( I), ( I), ( I)		O EIR
P		A	2016	.S.FDA			( I)		O EIR
C	R	M	2016	.S.FDA			I T R ,N D ) A (F P		P
G	P	M	2016	HO			P (OSD-I )		P
G	P	M	2016				P (INJ-I INJ-II )		P
H	M	12 16J	2016	D N (DN )			ISO13485 C ,CE C C II ,CEC C III		C II ,CEC Q
S	T	24 26A	2016	T R			EN ISO9001, EN ISO13485, CEC		P Q
T	L	30 31M	2016	T R LGA P G H			EN ISO 13485, EN I13485:2012/AC		Q

N : E A



## Medical safety

...T G...  
 ...I 2016, G...  
 ...A D R R M M S...  
 ...P...  
 ...G T G...  
 ...G...  
 ...T G...  
 ...I 2016, F P G...  
 ...2016.A 18...  
 ...G...  
 ...P...

## Central finance

...I 2016, G...  
 ...78... 61 API...  
 ...P G 2010 GMP... 53...  
 ...T, 13 API G...  
 ...H, L (MHL) G...  
 ...2 API (5 API) G P...  
 ...HO-PQC...  
 ...H C FDA S...




**13** API  
 ...e e e e e  
 cGMP Cert... ca

**1** ...  
**2** API (5 API)  
 G P  
 HO-PQC **1**  
 P H  
 C S FDA

F

P



H	C	M	D	S	F	P	G
N	T	N	R				
L	M	M	F	B	5	5	100%
			B		2	2	100%
			C	M	0	0	
					0	0	

# Ha d g fU er 'C a

T T G

.T .T

.C .I

2016, G 72

A

M P F P G

.A / .C

.C A

## Pr d cMeca

E G

2016, G 8

E

I 2016, F P G



100%

100%


8

0

I 2016,

G F P

# Marketing Excellence




C  
**>40,000**

H  
**>5,100**

O  
**>2,000**

M C F M D S





# Q a Safe Tra g

I  
M  
P  
G  
K  
GMP  
I 2016, G  
23  
I  
M  
P  
R  
S  
A  
F

# Ser Manager

S  
I 2016,  
P  
G S M F P G H S B G (T.),  
M ITP M M F P G (T.), M N -  
P P M S F P P G (T.), M M  
C P P S F P P (G) C, L (R), T.  
T D P P T S P F P, T P D  
D P T M S T T T D I  
P F P  
G  
S  
I 2016, F P  
C G 2016  
M F P T G  
I 2016, F P 447 557 110  
F T  
I 2016, F P  
F P  
I 2016, F P  
2015  
( / ), 671  
F P  
A F P ( )  
I G  
P  
D T  
T G  
S  
F P  
M  
T F  
M T F P

I 2016, F P


557

447

110

F P


671



S . . . M . . . M P . . . S . . . F P . . . G . . . 2016

S . . .	G . . P . .	B . . .	A . . P . .	E . . P . .	P . .
006010			25		

O T P . . . F P . . . S . . .



# Patient-Centered Medical Service

Through the implementation of the patient-centered medical service, we have achieved the following results:

## Medical Care and Education

In 2016, we have provided medical care and education to 20,000 patients and 2,300 medical staff members.

Through the implementation of the patient-centered medical service, we have achieved the following results:

In 2016, we have provided medical care and education to 20,000 patients and 2,300 medical staff members.

In 2016, we have provided medical care and education to 20,000 patients and 2,300 medical staff members.

In 2016, we have provided medical care and education to 20,000 patients and 2,300 medical staff members.

In 2016, we have provided medical care and education to 20,000 patients and 2,300 medical staff members.

In 2016, we have provided medical care and education to 20,000 patients and 2,300 medical staff members.

In 2016, we have provided medical care and education to 20,000 patients and 2,300 medical staff members.

In 2016, we have provided medical care and education to 20,000 patients and 2,300 medical staff members.

In 2016, we have provided medical care and education to 20,000 patients and 2,300 medical staff members.

In 2016, we have provided medical care and education to 20,000 patients and 2,300 medical staff members.

In 2016, we have provided medical care and education to 20,000 patients and 2,300 medical staff members.

In 2016, we have provided medical care and education to 20,000 patients and 2,300 medical staff members.


In 2016, we have provided medical care and education to 20,000 patients and 2,300 medical staff members.

In 2016, we have provided medical care and education to 20,000 patients and 2,300 medical staff members.

In 2016, we have provided medical care and education to 20,000 patients and 2,300 medical staff members.



Staff Training Session



Decrease in average number of staff members before and after

Year	Number of Staff Members
2016	2,300
2015	400

## Medical Care and Education

Through the implementation of the patient-centered medical service, we have achieved the following results:



A  
F P G

95.39%

.T ( )  
D 2016,  
M  
17.  
A ( )  
92%,  
95.39%. C H  
(N H F P C JKB),  
G P (G P H F P )  
C ) 2016.

C S S M S S F P G


S	J. C H	G H	H	C H	H G
S	97.8%	95%	95%	96.8%	92.32%


M F P

S	G H	C H	H	J. C H	H G
M	9	5	3	0	0

N :T

R P A S P C H (G P )







O C / D , F P







# Implementation of EHS Program

## Management of EHS System

Fosun Pharma Group & Subsidiaries Environment, Health & Safety (EHS) Management System



### Management

At the Moment of the Brand section of the 2016 Fosun Pharma annual meeting, the senior management members of Fosun Pharma (including the Chairman and President) signed the commitment for quality and EHS, and released the commitment to the stakeholders of Fosun Pharma that Fosun Pharma will create better and happier life for the people through innovation.



### Measurement System operation & Monitoring

to continue implement the guidelines and basic requirements described in Fosun Pharma The Environment, Health and Safety (EHS) handbook, including EHS seminars, EHS technical & awareness trainings, risk identification and assessment, cross audit, routine & non-routine inspection, EHS concern reported-out, and EHS red/yellow flagged issues. It's the first time to highlight and enhance the reporting-out requirement for EHS accident/incident/potential risks. The relating management team may finally be held accountable for their any violation to the incident report procedure, which aims to enhance the EHS management and control level and to minimize the EHS risks by strengthening the EHS management in a top-down approach.



### Group Internal Audit

the EHS audit scope within the subsidiary, with the five more subsidiaries, two more Business Units being involved in Y2016. Two major business units (medical diagnosis and medical devices) of Fosun Pharma Group for the first time, which marked the extended application of EHS management system on Fosun Pharma Group's subsidiaries in medium and smaller segments, and paved the way for intensive implementation of EHS system in Fosun Pharma Group.



### External Certification

The subsidiaries voluntarily took further steps to carry out external third party certification/assessment. By the end of Y2016, totally 10 subsidiaries of the Group received third party certifications of ISO 14001 and/or OSHAS 18001, and 21 subsidiaries passed the third party assessment on safety standardization of the PRC, representing an increase of 1 and 8 subsidiaries, respectively, as compared with last year.

Fosun Pharma Group		2016	
Subsidiary	Certification/Assessment	Subsidiary	Certification/Assessment
B	ISO14001, OHSAS18001, C III S S	E P	ISO14001, OHSAS18001, C III S S
J	ISO14001, OHSAS18001, C III S S	C P	ISO14001, OHSAS18001, C II S S
P	ISO14001, OHSAS18001, C II S S	P	ISO14001, OHSAS18001, C II S S
S S	ISO14001, OHSAS18001, C III S S	H P	ISO14001, OHSAS18001, C II S S
F	ISO14001, OHSAS18001, C III S S	J C H	ISO14001, C III S S
C B	T II S S	R P	T III S S
D P	T III S S	G H	T III S S
A	T III S S	L M M	T II S S
G P	T III S S	F B	T II S S
H P	T II S S	H a, Med ca	T III Safe Standard a
S T	T III S S		

## Case: The application of BBSWEC in the field of EHS

At the end of 2016, Fosun Pharma Group has successfully implemented the BBSWEC system in the field of EHS. The system is a comprehensive management system that integrates the EHS management system with the business process. It is designed to improve the EHS management level and reduce the EHS risks. The system is based on the BBSWEC model, which is a combination of the Best Business Practices, the Safety, and the Environmental Protection. The system is designed to be a comprehensive management system that integrates the EHS management system with the business process. It is designed to improve the EHS management level and reduce the EHS risks. The system is based on the BBSWEC model, which is a combination of the Best Business Practices, the Safety, and the Environmental Protection.




Figure 1: EHS隐患排查跟踪系统


# Environment, Health and Safety (EHS) Policy





Fosun Pharma Group has established this EHS Policy to define the Group's EHS management objectives and principles, and to provide a framework for the Group's EHS management system.


This Policy applies to all Fosun Pharma Group entities.


EHS


- 

1. Commitment to EHS: Fosun Pharma Group is committed to providing a safe and healthy working environment for all employees, and to protecting the environment. EHS is a core value of Fosun Pharma Group, and is integrated into all business activities.
- 

2. Environmental Protection: Fosun Pharma Group is committed to reducing environmental impacts, conserving resources, and promoting sustainable development. We will actively participate in environmental protection activities and work to improve our environmental performance.
- 

3. Prevention of Accidents: Fosun Pharma Group is committed to preventing accidents and incidents, and to ensuring the safety of all employees. We will implement strict safety measures and provide comprehensive safety training to all employees.
- 

4. Employee Health and Safety: Fosun Pharma Group is committed to promoting the health and safety of all employees. We will provide a safe and healthy working environment, and will actively participate in health and safety activities.
- 

5. Continuous Improvement: Fosun Pharma Group is committed to continuously improving our EHS performance. We will actively seek out opportunities for improvement, and will implement measures to address any identified issues.
- 

6. Compliance: Fosun Pharma Group is committed to complying with all applicable EHS laws, regulations, and standards. We will actively monitor and update our EHS management system to ensure compliance with the latest requirements.

Fosun Pharma Group will continue to improve our EHS performance, and to provide a safe and healthy working environment for all employees.

EHS



## Example C

- 1) ... :T  
 8,769,376 ... 52,439 0.6% ... 2015. I  
 ... 2016 139,000  
 ... 1.61% ... 2015. T ... 5.99 /  
 RMB10,000, ... 1.9 24.1%  
 D ... 2016, S ... S  
 396,000
- 2) E ... :T ... 478,175,186  
 53,707,564 12.7% ... 2015. I 2016,  
 D ... P ... F ... L ... T  
 ... ( / ) - ... D  
 ... S ... S ... G ... 2016.
- 3) O ... :O  
 185,690,272 ... 12,276,649 7.1%  
 ... 2015. O ... 126.93 /

## C ... E / C ... F P G

	T ( <sup>3</sup> / )	T ( / )	E ( / )	T ( / )	O ( / )	E ( )	RMB10,000	RMB10,000
								( <sup>3</sup> /RMB10,000)
2012	6,175,823	249,387,502		79,928,627				
2013	7,777,884	365,006,317	44,859,276	120,177,461	165,036,737			
2014	8,377,364	421,765,752	51,835,011	122,713,255	174,548,266	171.56		8.23
2015	8,716,937	424,467,622	52,209,518	121,204,106	173,413,623	157.01		7.89
2016	8,769,376	478,175,186	58,815,548	126,874,724	185,690,272	126.93		5.99

C O C		M E C		M S F P G		2016 ( R G P	
		( ³ )		( )		( )	
B		204,303		9,100,000		1,119,300	2,431,044
J		114,315		8,030,000		987,690	2,454,958
P		92,698		6,385,400		785,404	1,051,983
C B		59,910		7,021,980		863,704	1,102,893
F		8,960		1,353,675		166,502	512,647
S		24,310		333,900		41,070	102,515
D P		391,608		9,358,414		1,151,085	8,040,063
A		61,388		5,118,909		629,626	1,214,438
G P		720,702		30,072,609		3,698,931	6,550,133
S S		4,603,314		292,250,000		35,946,750	87,430,320
H P		39,259		2,634,503		324,044	451,782
A P		123,433		7,078,740		870,685	2,818,551
H P		45,236		1,021,655		125,664	596,698
E P		285,663		16,096,174		1,979,829	3,024,794
C P		123,820		6,018,550		740,282	1,010,622
P		348,581		29,640,192		3,645,744	3,808,225
T		12,952		29,119		3,582	265,678
T		109,823		513,300		63,136	272,628
S H		12,166		2,885,625		354,932	918,496
S T P		972		5,768,580		709,535	4,941
C R I		42,387		1,247,716		153,469	64,617
R P		12,543		2,416,970		297,287	422,558
F P		2,857		220,420		27,112	
G H		221,800		2,789,010		343,048	226,003
H		132,141		4,555,651		560,345	29,619
C H		511,000		11,930,000		1,467,390	1,187,084
J C H		185,316		1,666,000		204,918	95,700
G H		136,888		1,942,106		238,879	1,924
C M		820		246,443		30,312	531
B		6,531		804,042		98,897	6,938
L M M		5,613		1,858,608		228,609	21,369
F B		935		309,768		38,101	122
		1,044		158,182		19,456	
F M S		561		157,114		19,325	4,900
H M		34,500		1,218,783		149,910	36,813
C (B )		335		47,717		5,869	
C S		180		20,151		2,479	6,083
S T		36,885		2,884,972		354,852	390,632
L T		50,000		2,060,000		253,380	316,422
A		3,623		925,208		113,801	
C T		4		5,000		615	

B E C M S F P G 2016										
N	E	N	L	C	S	R	C	D	G	F
( )	( <sup>3</sup> )	( )	( <sup>3</sup> )	( )	( )	( )	( )	(L)	(L)	( )
B	9,100,000		15,600		27,112,000			200	74,300	
J	8,030,000		8,400		28,458,000					
P	6,385,400	5,338			11,997,000				15,080	
C B	7,021,980				12,629,320			5,301	12,569	
F	1,353,675	353,787	2,313					180	35,700	
S	333,900		1,800		955,000				16,500	
D P	9,358,414	1,283,596					8,855,000	350	6,898	
A	5,118,909		2,890		13,867,860				18,991	
G P	30,072,609	805,820					7,649,000	1,078	12,614	
S S	292,250,000						122,400,000			
H P	2,634,503		2,400		4,983,300			400	18,650	
A P	7,078,740		10,617	5,009,029				139,324	51,484	
H P	1,021,655		5,550					21,849	28,081	371,530
E P	16,096,174		831		34,829,000			4,008	29,705	
C P	6,018,550	41,846			11,135,340					
P	29,640,192	2,835,488						5,780	28,233	
T	29,119				2,979,000				9,600	
T	513,300	109,820						76,393	31,649	
S H	2,885,625							750,000	5,636	
S T P	5,768,580								4,651	
C R I	1,247,716	36,020							15,730	
R P	2,416,970				4,920,300			400	100	
F P	220,420									
G H	2,789,010	156,250						6,569	9,600	
H	4,555,651								8,289	14,569
C H	11,930,000	854,000						14,924	31,164	
J C H	1,666,000	48,985						5,900	22,000	
G H	1,942,106							10	1,800	
C M	246,443								500	
B	804,042								6,531	
L M M	1,858,608							100	20,000	
F B	309,768							100		
	158,182									
F M S	157,114							360	4,200	
H M	1,218,783							12,820	19,970	
C (B )	47,717									
C S	20,151							5,000		
S T	2,884,972							316,000	5,800	
L T	2,060,000	237,911								
A	925,208									
C T	5,000									

# Energy Conservation and Pollution Reduction

2016, FY, P, G  
 28,600, G, RMB7, I, G, 5,300,000

## Material

Material Category	Material Description	Material Description	Material Category
LED			

## Material

Material	Material Description	Material Description	Material	Material Description	Material Description	Material	Material Description
LED							
B							
C							
D							
E							
F							
G							
H							
I							
J							
K							
L							
M							
N							

\*N : D



## Water and electricity

In 2016, the Group's total consumption of water and electricity amounted to 8,769,376 m<sup>3</sup> (2015: 8,240,000 m<sup>3</sup>), an increase of 6.42% compared to 2015. The increase in consumption is mainly due to the expansion of the Group's operations in the Asia-Pacific region, particularly in China and India.


The Group's total consumption of water and electricity for the year amounted to 8,769,376 m<sup>3</sup> (2015: 8,240,000 m<sup>3</sup>), an increase of 6.42% compared to 2015. The increase in consumption is mainly due to the expansion of the Group's operations in the Asia-Pacific region, particularly in China and India.

T

6.42%



## Water management



2016

Region	Consumption (m <sup>3</sup> )	Total (m <sup>3</sup> )
North America	700	700
Japan	31,800	31,800
Europe	1,300	1,300
South America	2,500	2,500
Asia-Pacific	30,000	30,000
Africa	450	450
Global	29,000	29,000
Subsidiaries	396,000	396,000
Headquarters	3,552	3,552
Asia-Pacific Region (EDI)	11,550	11,550
Europe (F)	6,000	6,000
China (P)	960	960
India (P)	32,984	32,984
Headquarters (R)	300	300
China (C)	120	120
Latin America (M)	100	100
Headquarters (M)	7,415	7,415
Subsidiaries (S)	30	30

I 2016, G .D

---

Multiple sets of horizontal dotted lines for text entry.

N	T	N	T	A	R	R	
	1.R	C	( )	8,000	6,000	-	-
		C		1,030	859	-	-
	2.A	S		1,030	859	-	-
		E	( )	25.4	25.4	25.4	100%
S		A	( )	416	247	-	-
	3.P	M	(LDPE) ( )	2,000	660	-	-
		C		0	247	247	100%
		H	( ) ( )	1,000	500	-	-
		M		98,500	86,600	-	-
	1.R	L		70,000	62,000	-	-
		L		42,720	42,720	-	-
		T		67,520	67,520	45,000	66.6%
		D		2,000	1,529	-	-
D		L		20,300	17,490	-	-
P	2.A	C		16,375	11,687	-	-
		M		2,030	1,450.5	-	-
		S		3,503	3,703	-	-
	3.P	P	(0,000 )	1.43	1.42	0.14	9.6%
		P	(0,000 )	18.46	15.87	0.3	1.9%
	1.R	C	8.0(4 )			-	-
A							

( ) 17.9

N T N T A N 1.R

Multiple rows of horizontal dotted lines for text entry.


N	T	N	T	A	R	R
	1.R	P (0,000 )		474.94	474.75	-
		S ( )		1,749	1,657	-
T	2.A	A ( )		38	41	-
		R (L)		3,000	850	-
		P ( )		22	22.9	-
		A ( )		11.8	10.15	10.15 100%
S	1.R	G	N	N		
H	2.A	A	N	N		
	3.P	R	N	N		
	1.R	B		15	15	-
		T		15	15	-
		C 8.88 M		165	165	-
S	2.A	S		50-	G ,50-	OTH
T						
P						

---

Dotted lines forming a large table area.

---

⋮





Water average

T COD 490 2016,  
 0.5% 2015. T NH<sub>3</sub>-N 60.55  
 8.1% 2015. F P G



0 A

D G

D F P G 2016

N	T	D	COD	NH <sub>3</sub> -N				D
	( )	( )	( )	( )	( / )	( / )	( / )	
B	163,450	23.864	0.670					P
J	91,000	9.282	0.002					P
P	18,584	0.855	0.003					P
C B	53,919	1.941	0.511					T P
F	7,200	0.504	0.017					P
S	21,000	0.000	0.000		N			H T P
D P	313,286.4	18.703	2.115					D D C P
A	52,180	3.340	0.000					P
G P	576,562	40.359	0.000					P
S S	3,722,626	279.197	44.672					D R
H P	36,586	1.463	0.013					P
A P	80,000	9.600	0.000					P
H P	36,188	0.984	0.090					P
E P	197,104	16.872	0.487					P
C P	80,937	3.262	1.531					S F D C L
P	96,417	3.754	0.329					P
T	12,952.26	2.590	0.000					Q T C
T	93,349.65	0.000	0.000					P S N D P
S H	6,083	0.274	0.091					T C
S T P	972	0.292	0.010					P
C R	33,909.6	3.221	0.458					P
R P	12,150	3.038	0.122					P
F P	2,285.6	0.217	0.031					P
G H	221,800	12.643	0.956		N			D L
H	118,926.9	3.496	0.035					C
C H	332,279	8.307	5.316					C
J C H	148,252.8	12.572	1.097					P
H G	136,194	9.806	1.634					P
C M	656	0.033	0.005		N			P
B	6,531	0.000	0.000		N			P
L M M	5,052	0.808	0.019					P
F B	842	0.135	0.003					P
	1,043.57	0.000	0.000		N			P
F M S	505	0.000	0.000		N			P
H M	27,600	2.208	0.276					D
C (B )	335	0.000	0.000		N			D
C S	180	0.000	0.000		N			D
S T	33,196.5	16.233	0.050		N			P
L T	40,000	0.000	0.000					P
C T	4	0.000	0.000		N/A	N/A	N/A	



## Case: Waste Water Treatment & Sludge Treatment

Industrial effluent from RMB5.11, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189, 190, 191, 192, 193, 194, 195, 196, 197, 198, 199, 200, 201, 202, 203, 204, 205, 206, 207, 208, 209, 210, 211, 212, 213, 214, 215, 216, 217, 218, 219, 220, 221, 222, 223, 224, 225, 226, 227, 228, 229, 230, 231, 232, 233, 234, 235, 236, 237, 238, 239, 240, 241, 242, 243, 244, 245, 246, 247, 248, 249, 250, 251, 252, 253, 254, 255, 256, 257, 258, 259, 260, 261, 262, 263, 264, 265, 266, 267, 268, 269, 270, 271, 272, 273, 274, 275, 276, 277, 278, 279, 280, 281, 282, 283, 284, 285, 286, 287, 288, 289, 290, 291, 292, 293, 294, 295, 296, 297, 298, 299, 300, 301, 302, 303, 304, 305, 306, 307, 308, 309, 310, 311, 312, 313, 314, 315, 316, 317, 318, 319, 320, 321, 322, 323, 324, 325, 326, 327, 328, 329, 330, 331, 332, 333, 334, 335, 336, 337, 338, 339, 340, 341, 342, 343, 344, 345, 346, 347, 348, 349, 350, 351, 352, 353, 354, 355, 356, 357, 358, 359, 360, 361, 362, 363, 364, 365, 366, 367, 368, 369, 370, 371, 372, 373, 374, 375, 376, 377, 378, 379, 380, 381, 382, 383, 384, 385, 386, 387, 388, 389, 390, 391, 392, 393, 394, 395, 396, 397, 398, 399, 400, 401, 402, 403, 404, 405, 406, 407, 408, 409, 410, 411, 412, 413, 414, 415, 416, 417, 418, 419, 420, 421, 422, 423, 424, 425, 426, 427, 428, 429, 430, 431, 432, 433, 434, 435, 436, 437, 438, 439, 440, 441, 442, 443, 444, 445, 446, 447, 448, 449, 450, 451, 452, 453, 454, 455, 456, 457, 458, 459, 460, 461, 462, 463, 464, 465, 466, 467, 468, 469, 470, 471, 472, 473, 474, 475, 476, 477, 478, 479, 480, 481, 482, 483, 484, 485, 486, 487, 488, 489, 490, 491, 492, 493, 494, 495, 496, 497, 498, 499, 500, 501, 502, 503, 504, 505, 506, 507, 508, 509, 510, 511, 512, 513, 514, 515, 516, 517, 518, 519, 520, 521, 522, 523, 524, 525, 526, 527, 528, 529, 530, 531, 532, 533, 534, 535, 536, 537, 538, 539, 540, 541, 542, 543, 544, 545, 546, 547, 548, 549, 550, 551, 552, 553, 554, 555, 556, 557, 558, 559, 560, 561, 562, 563, 564, 565, 566, 567, 568, 569, 570, 571, 572, 573, 574, 575, 576, 577, 578, 579, 580, 581, 582, 583, 584, 585, 586, 587, 588, 589, 590, 591, 592, 593, 594, 595, 596, 597, 598, 599, 600, 601, 602, 603, 604, 605, 606, 607, 608, 609, 610, 611, 612, 613, 614, 615, 616, 617, 618, 619, 620, 621, 622, 623, 624, 625, 626, 627, 628, 629, 630, 631, 632, 633, 634, 635, 636, 637, 638, 639, 640, 641, 642, 643, 644, 645, 646, 647, 648, 649, 650, 651, 652, 653, 654, 655, 656, 657, 658, 659, 660, 661, 662, 663, 664, 665, 666, 667, 668, 669, 670, 671, 672, 673, 674, 675, 676, 677, 678, 679, 680, 681, 682, 683, 684, 685, 686, 687, 688, 689, 690, 691, 692, 693, 694, 695, 696, 697, 698, 699, 700, 701, 702, 703, 704, 705, 706, 707, 708, 709, 710, 711, 712, 713, 714, 715, 716, 717, 718, 719, 720, 721, 722, 723, 724, 725, 726, 727, 728, 729, 730, 731, 732, 733, 734, 735, 736, 737, 738, 739, 740, 741, 742, 743, 744, 745, 746, 747, 748, 749, 750, 751, 752, 753, 754, 755, 756, 757, 758, 759, 760, 761, 762, 763, 764, 765, 766, 767, 768, 769, 770, 771, 772, 773, 774, 775, 776, 777, 778, 779, 780, 781, 782, 783, 784, 785, 786, 787, 788, 789, 790, 791, 792, 793, 794, 795, 796, 797, 798, 799, 800, 801, 802, 803, 804, 805, 806, 807, 808, 809, 810, 811, 812, 813, 814, 815, 816, 817, 818, 819, 820, 821, 822, 823, 824, 825, 826, 827, 828, 829, 830, 831, 832, 833, 834, 835, 836, 837, 838, 839, 840, 841, 842, 843, 844, 845, 846, 847, 848, 849, 850, 851, 852, 853, 854, 855, 856, 857, 858, 859, 860, 861, 862, 863, 864, 865, 866, 867, 868, 869, 870, 871, 872, 873, 874, 875, 876, 877, 878, 879, 880, 881, 882, 883, 884, 885, 886, 887, 888, 889, 890, 891, 892, 893, 894, 895, 896, 897, 898, 899, 900, 901, 902, 903, 904, 905, 906, 907, 908, 909, 910, 911, 912, 913, 914, 915, 916, 917, 918, 919, 920, 921, 922, 923, 924, 925, 926, 927, 928, 929, 930, 931, 932, 933, 934, 935, 936, 937, 938, 939, 940, 941, 942, 943, 944, 945, 946, 947, 948, 949, 950, 951, 952, 953, 954, 955, 956, 957, 958, 959, 960, 961, 962, 963, 964, 965, 966, 967, 968, 969, 970, 971, 972, 973, 974, 975, 976, 977, 978, 979, 980, 981, 982, 983, 984, 985, 986, 987, 988, 989, 990, 991, 992, 993, 994, 995, 996, 997, 998, 999, 1000

## Case: Upgrade of Waste Water Treatment & Sludge

Large scale upgrade of waste water treatment plant. The project includes the construction of new treatment tanks, aeration systems, and sludge handling facilities. The plant is designed to handle a flow rate of 600 m<sup>3</sup>/day. The treatment process involves primary treatment (I, II), secondary treatment (A/O), and sludge treatment (TRIC). The plant is located in an industrial area and is surrounded by a fence. The project was completed in 2016.



Area

A. E... F P G 2016

N	N	S	P	N	T
( / )	( / )	( / )	( / )	( / )	
J	0.000	0.001	0.000	0.12	A ;B F
P	0.000	0.010	0.130	0.07	
F	3.359	0.611	0.370	0.00	F
D P	0.002	0.001	0.000	0.00	D
G P	32.863	23.886	8.817	0.00	D
S S	419.839	441.936	6.187	0.00	D +
A P	0.000	15.747	1.030	0.00	N/A
H P	3.384	2.269	1.086	0.00	E
E P	0.869	0.000	0.185	0.00	E 35-
C P	0.000	0.000	0.000	1.34	M + 20.
P	4.007	0.180	0.604	0.00	D
S T P	0.000	0.000	0.000	0.01	D
C R I	0.03	0.038	0.013	-	D
R P	0.000	0.000	0.000	0.55	O + +
C H	1.414	0.000	0.007	0.00	1.1 2.
L M M	0.002	0.000	0.000	0.00	E
S T	0.010	0.014	0.014	0.00	N/A

Case: Better Project for Carbon - Ga Eecy c C er

T... T... I... A... D 2016, D P, F L, T

Case: Tra f a... Project for a Mega c eced... f ca

G P RMB2... T ( ... ( OC) ... T

**S d a t a a g e e**

I 2016, F P G 80,848.14 .D P  
F L T 3,158  
( ) 909

I 2016, G  
E

D. 2016

N	T								
	( )	( )	( )	( )	( )	( )	( )	( )	( )
H	229.67	146	0	83.67	0	83.67	0	0	H
C H	738	535	0	203	0	203	0	0	H
J C H	23.87	11.91	11.91	0.04	0	0.04	0	0	H
H G	192	75	0	117	0	0	0	117	H
C M	0.67	0.63	0.02	0.02	0	0	0	0.02	H
B	15.3	9.6	0	5.7	0	2.5	0	3.3	H
L M M	25.3	12	12	1.3	0	1.3	0	0	H
F B	3.37	2.08	1.08	0.21	0	0.21	0	0	H
	0.84	0.75	0	0.09	0	0.09	0	0	H
F M S	1.51	1.5	0.01	0	0	0	0	0	C
H M	63	60	3	0	0	0	0	0	S
C (B )	13	13	0	0	0	0	0	0	C
C S	0.5	0.5	0	0	0	0	0	0	C
S T	15	5	10	0	0	0	0	0	C
L T	78	50	28	0	0	0	0	0	C
C T	0.08	0.08	0	0	0	0	0	0	C


I. 2016

N	E	
	P	A (RMB10,000)
B O		9.30
J T		519.20
P C		45.00
C B T		0.35
F E		22.90
S A		5.00
D P T H PS		20.00
A E		1.00
G P T		206.00
S S R		218.00
H P E		1.21

Executive Summary

In 2016, the Group's operating profit was RMB33.46 million, an increase of RMB13.19 million from RMB20.27 million in 2015.

Revenue



Income Statement for the Year Ended December 31, 2016

Notes	2016 A (RMB10,000)	2015 A (RMB10,000)
Revenue	3,346	3,166
Cost of sales	(1,980)	(1,850)
Gross profit	1,366	1,316
Selling and distribution expenses	(1,000)	(950)
Administrative expenses	(1,000)	(950)
Finance income	10	10
Finance expenses	(10)	(10)
Other income	10	10
Other expenses	(10)	(10)
Operating profit	33.46	20.27
Income tax expense	(10)	(10)
Profit after tax	23.46	10.27
Other comprehensive income	10	10
Profit for the year	33.46	20.27

# GreenSource

In 2016, GreenSource Pharmaceuticals, Inc. ("GreenSource") was recognized as a "Best of Breed" company by the Environmental Business Awards (EBA) for its commitment to environmental stewardship. GreenSource was also recognized as a "Best of Breed" company by the Environmental Business Awards (EBA) for its commitment to environmental stewardship.



# Acțiunile climatice

## Emisiile de gaze de seră

În 2016, grupul a emis 750,000 tone echivalente de CO<sub>2</sub> (tCO<sub>2</sub>e) în cadrul activităților operaționale. Emisiile de gaze de seră au scăzut cu 10% față de anul 2015, datorită creșterii eficienței energetice și a utilizării energiei regenerabile.

Activitatea noastră este acoperită de un sistem de gestionare a emisiilor de gaze de seră în conformitate cu ISO 14064-1:2013 și este verificată de un organism acreditat.

În 2016, grupul a emis 750,000 tCO<sub>2</sub>e în cadrul activităților operaționale. Emisiile de gaze de seră au scăzut cu 10% față de anul 2015, datorită creșterii eficienței energetice și a utilizării energiei regenerabile.

Activitatea noastră este acoperită de un sistem de gestionare a emisiilor de gaze de seră în conformitate cu ISO 14064-1:2013 și este verificată de un organism acreditat.

Măsurile noastre de reducere a emisiilor de gaze de seră includ:
 

- Optimizarea proceselor de producție și distribuție.
- Utilizarea energiei regenerabile.
- Investiții în echipamente eficiente energetic.
- Promovarea economiei de energie printre clienții noștri.

## Ca de Ne, c... ced... ar... er... a... e

T... A... În 2016, grupul a emis 120,000 tCO<sub>2</sub>e în cadrul activităților operaționale. Emisiile de gaze de seră au scăzut cu 10% față de anul 2015, datorită creșterii eficienței energetice și a utilizării energiei regenerabile.



## Ca de Tra f... a... f... e... ca... agearea


T... În 2016, grupul a emis 416,000 tCO<sub>2</sub>e în cadrul activităților operaționale. Emisiile de gaze de seră au scăzut cu 10% față de anul 2015, datorită creșterii eficienței energetice și a utilizării energiei regenerabile.

I 2016, F P G  
 .I  
 .A  
 S  
 A 2016,9 F P G  
 F 2016, F P G EHS  
 ( T )  
 .I  
 , F P G



## Occ a a ea a d afe


F P G  
 .I 2016, F P  
 I 2016 , F P 0 , 703



### Safety

F P  
 ( ) .T EHS  
 GB6441-86 <T S C I A F I  
 E E > OSHA .L  
 ( )  
 I 2016, 20 0.044 (8 ) , 0.072 (13 )  
 , 0.116 (21 ) ( ) , 0.21 (38 )  
 C 2015, 69.6%,  
 81.7%, 72.7%,  
 60.7%. A

A 2016



A 2016

F P  
 F P (PSM) API  
 .A .B 2016, 0





F P ... ,EHS

S I F P G 2016

N	T	T	I						I				IH	D	LTC	
			M	S	N	N	N	I	F	L	R	L				R
		( )						200,000	200,000							
B	779	1,607,070	0	0	1	0	1	0.12	0.00	1	3	0.12	0.37	0	105	
J	169	344,110	0	0	0	0	0	0.00	0.00	0	0	0.00	0.00	0	0	
P	306	708,990	0	0	0	0	0	0.00	0.00	0	0	0.00	0.00	0	0	
C B	157	375,303	0	0	0	1	1	0.53	0.00	1	2	0.53	1.07	0	40	
F	210	443,520	0	0	0	0	0	0.00	0.00	0	0	0.00	0.00	0	0	
S	98	250,880	0	0	0	0	0	0.00	0.00	0	0	0.00	0.00	0	0	
D P	943	1,968,984	0	0	1	1	2	0.20	0.00	2	3	0.20	0.30	0	212	
A	301	660,030	0	0	0	0	0	0.00	0.00	0	1	0.00	0.30	0	0	
G P	1,155	2,310,000	0	0	0	2	2	0.17	0.00	2	3	0.17	0.26	0	84	
S S	1,860	4,464,000	0	0	3	0	3	0.13	0.00	3	3	0.13	0.13	0	350	
H P	289	622,104	0	0	0	0	0	0.00	0.00	0	0	0.00	0.00	0	0	
A P	613	1,331,090	0	0	0	0	0	0.00	0.00	0	1	0.00	0.15	0	0	
H P	369	734,768	0	0	0	0	0	0.00	0.00	0	5	0.00	1.36	0	0	
E P	789	1,841,777	0	0	0	2	2	0.22	0.00	2	2	0.22	0.22	0	65	
C P	316	740,918	0	0	1	2	3	0.81	0.00	3	5	0.81	1.35	0	160	
P	1,195	2,495,160	0	0	0	1	1	0.08	0.00	1	2	0.08	0.16	0	25	
T	88	198,904	0	0	0	0	0	0.00	0.00	0	0	0.00	0.00	0	0	
T	28	6,368	0	0	0	0	0	0.00	0.00	0	0	0.00	0.00	0	0	
S H	292	511,704	0	0	0	0	0	0.00	0.00	0	0	0.00	0.00	0	0	
S T P	95	198,360	0	0	0	0	0	0.00	0.00	0	0	0.00	0.00	0	0	
C R	248	496,000	0	0	0	0	0	0.00	0.00	0	0	0.00	0.00	0	0	
R P	148	340,000	0	0	0	0	0	0.00	0.00	0	0	0.00	0.00	0	0	
S F	31	80,600	0	0	0	0	0	0.00	0.00	0	0	0.00	0.00	0	0	
G H	541	1,137,552	0	0	0	0	0	0.00	0.00	0	0	0.00	0.00	0	0	
H	660	1,326,480	0	0	0	0	0	0.00	0.00	0	0	0.00	0.00	0	0	
C H	1,700	4,406,400	0	0	1	3	4	0.18	0.00	4	6	0.18	0.27	0	270	
J C H	307	677,856	0	0	0	0	0	0.00	0.00	0	0	0.00	0.00	0	0	
G H	291	584,328	0	0	0	0	0	0.00	0.00	0	0	0.00	0.00	0	0	
C M	19	30,818	0	0	0	0	0	0.00	0.00	0	0	0.00	0.00	0	0	
F M -T	151	280,000	0	0	0	0	0	0.00	0.00	0	0	0.00	0.00	0	0	
L M M	321	656,588	0	0	0	0	0	0.00	0.00	0	0	0.00	0.00	0	0	
F B	18	36,860	0	0	0	0	0	0.00	0.00	0	0	0.00	0.00	0	0	
	67	102,137	0	0	0	0	0	0.00	0.00	0	0	0.00	0.00	0	0	
F D	89	154,784	0	0	0	0	0	0.00	0.00	0	0	0.00	0.00	0	0	
H M	577	1,505,970	0	0	0	0	0	0.00	0.00	0	0	0.00	0.00	0	0	
C (B )	51	96,024	0	0	0	0	0	0.00	0.00	0	0	0.00	0.00	0	0	
C S	126	245,844	0	0	0	0	0	0.00	0.00	0	0	0.00	0.00	0	0	
S T	231	616,875	0	0	1	0	1	0.32	0.00	1	1	0.32	0.32	0	110	
L T	186	428,544	0	0	0	0	0	0.00	0.00	0	0	0.00	0.00	0	0	
A	213	444,744	0	0	0	0	0	0.00	0.00	0	1	0.00	0.45	0	0	
C T	4	3,392	0	0	0	0	0	0.00	0.00	0	0	0.00	0.00	0	0	

Note: 1. 1 minor injury incident in the headquarter of the Fosun Pharma Group was included in the lost-time cases and recordable injury cases;

2. (Total, Lost-time, Recordable) Rate = (Total, Lost-time, Recordable) Number \* 200,000 / Total Working Hours

### Ca e: I e e e ce afe R e P a a


R P RMB6.05 DCS, API F R DCS API

### Ca e: Mec a ca e e e e e e

I F D C S I 2016, F D C S T A

### Occ a a Hea

F P ( )  
D F P ( )  
I 2016, 2,417 100%  
0.T 100%.







**I F P G**

N		P		A		P		A	
				(RMB10,000)				(RMB10,000)	
F	M	I	(	9.50	P			3.80	
H	M	E		1.10				2.70	
C	(B	)			A		OTC		0.08
S	T	P		13.00	S			5.00	
L	T	F		0.70	I			1.00	

**E ee E gage e**

F P EHS C F L

EHS

T EHS

I 2016, F P EHS T

93,431 34,913 2.15

5.75 T 22.2%

2015.

---

---

---

---

---


---

---

---

---

---





S	M				M
B	EHS EHS	B	R	EHS	
J	EHS	F		A C	R EHS
F	EHS	T	7		LOTO EHS
S	EHS	T	A	EHS	B
D	P	EHS	T C A J	C O F N	H I ( ) A ;E GMP A EHS ;2015
A	S	S			
G	P	EHS	C		S
H	P	EHS	I		EHS
A	P	S	S	A C	MSDS
H	P	EHS	R	EHS	EHS ( )
E	P	EHS	H	EHS	EHS
EHS B	P EHS	1. 2. 3. 4.C 5.I	EHS	EHS	
T	S	C			
T	EHS	T	H		
S	H	EHS	H		
S	T	P	EHS	F	
R	C	I	EHS	A	EHS EHS
R	P	S	H	4	3 2 2 11
S	F	L	C		
H	EHS	T		EHS	T 5 EHS
L	M	EHS	S		EHS
F	B	EHS	S		EHS
H	M	EHS	T		11 N 2016
S	T	S	R	EHS	EHS
L	T	EHS	F		A C EHS


Disclosure description: 1. The report discloses the health, safety and environmental protection quality, which is part of the working environment quality and has important effect on the Group. They include the related important performance indicators. For some key indicators which have general effect on the Group, the report has also made voluntary disclosure to some extent. 2. Six new subsidiaries, namely Wanbang Tiancheng, Wanbang Tiansheng, Fuchuang Pharma, Wen hou Geriatrics Hospital, Zhongsheng Zhongjie and Chindex Tianjin, were included in the major subsidiaries disclosed. 3. The calculation method of total number of employees in EHS section is different from the calculation method of total number of employees in Employees section in this report, the statistical scope of number of employees for EHS section is the number of employees in service.

Data description: the statistics of the data disclosed in the above sections and each table in the EHS report are conducted in accordance with related national or local regulations, industrial standards, administrative requirements or practices formulated by subsidiaries. They are derived after reasonable verification. For the data whose validity or completeness cannot be confirmed due to various objective reasons, they are denoted with "X". For the appropriate data, they are denoted with "NA".







### Yearly growth



### Percentage




### Value of R&D



### Take-down



### Employee



### There are a few of the group's cash

Cash payment to employees and on behalf of employees

(RMB100,000,000)

In 2016, the Group's cash payment to employees and on behalf of employees totaled RMB 2,196 million,

# Sustainable Development Goals

## Take Action

Target 12.2: By 2030, achieve the sustainable consumption and production goal, to significantly reduce waste generation

S	H	R	F	P	G	(P)
					G	
			T	M	F	
2016			19,523	9,574	9,949	
2015			17,842	8,653	9,189	
2014			18,081	8,800	9,281	
2013			16,791	8,246	8,545	
2012			14,357	7,222	7,135	

E	B	E	F	P	G	(Pe e)
		D	M	B	D	S
2016		134	1021	5,395	4,977	7,996
2015		105	889	4,453	4,643	7,752
2014		93	749	4,229	4,693	8,317
2013		80	637	3,794	4,368	7,912
2012		50	472	2,931	3,364	7,540

R	F	P	G	:(	)	(P)				
		R	N	2015	N	2016				
E	C	(S	,J	,A	,F	,S	)	7,803	8,869	
S	C	(G	,G	,H	)		3,144	3,276		
C	C	(H	,H	,H	,J	)	3,110	3,442		
N	C	(B	,T	,H	,S	,I	M	)	176	191
N	C	(N	,Q	,S	,G	)	-	-		
S	C	(S	,G	,T	,C	)	2,038	2,001		
N	C	(L	,J	,H	)		1,256	1,387		
H	K	,M	T					14		
O							315	343		

## Ta e Ed ca


F P

T G


I 2016, C S M P

T R

F P




**Learning Development Strategy**



# Case: Establishment of Faculty of Food and Agricultural Engineering at Tsinghua University

During the process of establishing the Faculty of Food and Agricultural Engineering at Tsinghua University, the company has provided technical support and training for the faculty members. In 2016, the company provided technical support and training for the faculty members.



The company has provided technical support and training for the faculty members. In 2016, the company provided technical support and training for the faculty members.

The company has provided technical support and training for the faculty members. In 2016, the company provided technical support and training for the faculty members.

T	S	B	C	N	C
D	T	T	R	T	B
N	H	S	M	T	G
N	M	S	C	N	I
M	T24	N	S	HQC	O
S	C	F	P	O	C
M	L	S	P	L	M
Q	P	T	N	GMP	GMP
EHS	N	E	O	EHS	E







## Case: Trao đổi và Chương trình của Hội thảo Kỹ thuật năm 2016

S.T.P. ...



### T... S... S.T.P...

C	N	C
N H S	P	F D
P T	T	F P
T D	E	T T
M	S	S



## Case: TeC e g f e F Se ar Ma age e f C e ar H a f P ar a f e Pre de

I... F P... F P... F S... M... C... H... F P... G... P... T P... S... N... 2016.S... G... 120... C Q... C... F P... T C... E... F



S... P...



## Case: Trao đổi và Chương trình của Hội thảo Quản lý và Lãnh đạo các Doanh nghiệp (CML)

T... S... M... P... F... P... G... C... (CML)... L... E... M... R... M... T... :P... 2-... T... M... E... G... T... M... C... (CML)



# E e e De e e e

## Perf a ce a age e

T ... G ... KPI ...


F ... P ... G ... KPI ...

E ... B ... D ... B ... D ...

... A ...

.43

F ... P ... - ... T ... 0 ( ) 6 ( ) 6.1 ( ) -4 ... ( )



S F P (P )

S F P 2012 2013 2014 2015 2016

T

☒

---

---

---

---

---

---

---

---

---

---

## Employee Activities

Employee activities are important to the corporate cultural construction of Fosun Pharma Group. The Corporate Culture Working Committee ( Culture Working Committee) of Fosun Pharma fully utilizes the resources of the organization, proactively organizes and coordinates among individual departments and individual subsidiaries with the support from various aspects such as the labor union, administration, human resources and branding and joins efforts in the organization of various events that help invigorate employees' cultural life and jointly proceed corporate cultural constructions.

To create an innovative culture within Fosun Pharma Group, in the first half of 2016, Fosun Pharma organized the Fosun Pharma 2016 Innovation Contest named "Xingrong e-action" which aims to identify innovative talent within the Group, uncover high quality projects and to provide support for an innovative internal environment. In view of the Unicorn Potential Award and Business Innovation Award, the contest has received a total of 98 pieces of work, with more than 900 audiences voting to ultimately decide the winner.

In 2016, the labor unions of Fosun Pharma and its subsidiaries organized over 350 cultural and sports activities, including various festival caring events for employees such as Chinese New Year, Lantern Festival, International Women's Day, Children's Day, Mid-Autumn Festival, Chung Yeung Festival, Children's Day, high temperature allowance, birthday parties, employee physical examination and street market activities, as well as various employees' club activities. Fosun Pharma Group has established 12 employees' clubs which will organize various activities welcomed by the employees regularly. Meanwhile, each club proactively participates in neighborhood activities and community interaction through the



The Meeting Online



G...P... F...P... CME  
 .O...  
 A...T... A...  
 A...  
 T... G...P...  
 D.C...D...H...M...





P b c e fare c y b

C er ce


>300 e  
V e e e a  
a c e

>90 e  
P b c e fare ea  
a a d ea  
c a

F e g a d e c

1 P e c

H e



# Share Value

In 2016, the company's share value increased by RMB2.99.\*

Share value is calculated based on the closing price of the company's shares on the Hong Kong Stock Exchange on December 31, 2016, minus the closing price on December 31, 2015.

\*Net change in share value = (Closing price on December 31, 2016 - Closing price on December 31, 2015) x Number of shares outstanding at the end of 2016



In 2016, the company's share value increased by **RMB2.99**

**8.3%**  
RMB 2.76 (2015)

# Corporate Governance

The company has established a robust corporate governance framework to ensure the company's long-term sustainable development. This framework is based on the principles of transparency, accountability, and fairness, and is designed to protect the interests of all stakeholders.

The company's corporate governance structure includes the following key elements:

- Board of Directors:** The Board is responsible for the overall management and supervision of the company's business and operations. It consists of independent non-executive directors, executive directors, and non-executive directors.
- Supervisory Board:** The Supervisory Board is responsible for supervising the company's financial activities and the performance of its directors and senior management.
- Senior Management:** The Senior Management is responsible for the day-to-day management of the company's business and operations.

The company's corporate governance framework is designed to ensure the company's long-term sustainable development and to protect the interests of all stakeholders.



F P

T

I 2016, F A S D S C T  
C  
I D OA F P F A S  
D  
A 42

### Fid car, Ad va S er De ar e

T  
C B D F A 2016,  
A S D C F  
C C

I 2016, F A S  
D P A C O B D T  
E F P T H P M R  
S F A A S S D I  
F A S D  
A 23

T F A S D

M F A S D  
I 2016, F A S D  
ISO19600 C M S G

### C Car

F P  
RMB7.97 I 2016, F P G

### I crea ed de efec g e FUTURE STAR c car c e

F P G  
F P G  
P G F T RE STAR 1998.F

### F F da

I 2016, F P RMB5.00 F F A S B C.C.T  
L S D F D T A T


### Targeted P er A e a

F P G C



I 2016, F P  
F F

RMB5



G...  
 C... F... P... G...  
 I 2016, F... P...  
 RMB6.45...  
 F... P... H... P... RMB1,000,000... C...  
 A... A... F... F... D... T...  
 A...  
 F... P... L... S... F... C... P... C...  
 RMB150,000... 29... (F... I 2016,  
 10... ;C... P... :15... ).  
 J... C... H... F... P... 100... 60...  
 RMB5,000,000...  
 T... P... C... H... 9...  
 B... RMB30,000... J... A... P... 30...  
 M... L... T... C... F...  
 RMB50,000... J... C... F... 207...  
 H... C... 17... O... 2016... P... P... A... D...  
 A... B... G... 2016, G... P... RMB60,000... T...  
 H... J... F... A... P... C... C... F... D...  
 A... G... C... D... G... C... C... C... F... I... R...  
 I... Q... D... I 2016, C... R... I...  
 RMB150,000... Q... D...



L... P... I... T...  
 M... C... F...  
 P...  
 C... M...

---

## Case: Joined force with Shanghai Charity Foundation to provide support to patients suffered from cancer

On 9 September, the charity day, Shanghai Charity Foundation, Fosun Foundation and Shanghai Symphony Orchestra jointly organized the charity concert of Fosun Charity Night: Let Love Fill the New World. All the donations in the event were collected through various mobile and internet charity platforms such as Tencent, Alipay, official WeChat account of Fosun Foundation (fosunfoundation) and the official website of Shanghai Symphony Orchestra, and were donated to Shanghai Charitable Cancer Research Center to finance the doctors and scientific researchers in Shanghai who devote in cancer clinical research, so as to work out the best treatment solutions for patients suffered from cancer as soon as possible.

## Case: Double Thousand Actions provided timely support and care to all patients suffered from tuberculosis

On 22 March, at the promotion event of World Tuberculosis Day, Chinese Antituberculosis Association established the Chinese Anti-tuberculosis Non-profit Foundation and jointly launched the Chinese Anti-tuberculosis Non-profit Foundation - Double Thousand Actions assistance project for tuberculosis with Fosun Foundation and Hongqi Pharma (a subsidiary of Fosun Pharma). The Double Thousand Actions project will last for five years from 2016 to 2020. At least 1000 needy patients suffering from tuberculosis can be helped each year and the funding for each patient would not be less than RMB1,000. Fosun Foundation collaborates with Hongqi Pharma, a subsidiary of Fosun Pharma, to provide continuous sponsorship in the form of funding and medicine etc.

On 27 April, the 2016 National Academic Meeting of Chinese Antituberculosis Association was held in Zhuhai, Guangdong Province, and the unveiling ceremony of Chinese Anti-tuberculosis Non-profit Foundation took place at the opening ceremony.

## Case: Organization of the 2nd Climb for Charity Competition by Fosun Pharma with the donation allocated to Qixiang Institute of Child Development

In February, the Climb for Charity Competition co-organized by Fosun Foundation and Fosun Pharma was held in the headquarter building of Fosun Pharma. About 22 teams participated the activity with participants covering staff of Fosun Pharma and their families, media as well as other stakeholders. All teams completed the competition within required time. The competition finally raised a total donation amount of RMB66,000.

A meeting to allocate the donation from the Climbing for Charity Competition was held in April. Six project leaders of the public welfare projects which applied for the donation presented their projects. After the voting, the Family of Children with Special Needs Rehabilitation Support Program by Shanghai Qixiang Institute of Child Development was granted the donation.

## Case: Walking for Love the Shanghai United Walkathon Volunteer Event was held again

In April 2016, the Shanghai United Walkathon Volunteer Event was held again. Participants and volunteers of Fosun Pharma participated the event with full enthusiasm despite of the bad weather. With the support, accompany and encouragement of teammates and the Company's volunteers, the whole 12-hour walkathon covering a total of 50 kilometers was completed successfully with full love. Fosun Pharma volunteers have participated in the Shanghai United Walkathon charity event for four successive years and raised over RMB300,000 for supporting the children nutrition in poor areas, rural children's reading, children with autism, quality training for migrant children as well as other sectors.

## Case: the Bang Program Trying the best to participate in public welfare activities

As the extension of the Company's core value of self-improvement, teamwork, performance and contribution to society as well as the inheritance of the public welfare mission of trying the best to participate in public welfare activities, the Bang Program public welfare project team expanded the activity scope in 2016 to further cover more students in poverty and fundamental hospitals in remote areas. Through preliminary study and careful selection, in 2016, the Bang Program public welfare project team of Wanbang Biopharma visited Yuanyang County and Zhengzhou in Henan Province, Jingxing County in Hebei Province and Suining County in Jiangsu Province, carried out in-depth interaction with the grassroots, supported the local education and healthcare, and further improved the local educational and medical conditions and levels, which was well recognized and encouraged by the supported students in poverty areas, fundamental medical works and experts participated in the activities.



## Value for Tea

T... F... P... 100... S...  
 2010, F... P...  
 F... P...  
 H... S... C...  
 F... P... S... C... I... S... 2010,  
 E... I... J...  
 F... P... T... M... D... S... C... I...  
 Q... T... M... D... S... C... I...  
 F... F... L... S... C... I...  
 T... F... P... S... S... M... S... (F... P... M... D...),  
 D... G... P... L...  
 L... C... L... T... 25... T... F... P... 17,000  
 30...  
 C... H... 10... L... N...  
 1,100... G... H... S... S... A... H...  
 3... 5... T... G... H...

## Customer Service

I 2016, G... 100...  
 A... P... H... I... J... C... F... S...  
 207... G... C... P... S... T... H...  
 J... T... H... C... C... P... S... T... H...  
 C... B... D... P... C...  
 N... T... M...  
 T...  
 D... 90...  
 T... 2016, G... H...  
 5,000... 2... 3... M... G... H... T... E... P...  
 J... C... H... M... A... P... R... C... F... S...  
 65-... M... T... P... P... 65... C... F... S...  
 S... C... H... 21... T... I 2016,  
 C... H... A...



T... 90...  
**>90**



G... H...



O... H... D... C...  
 H... R... D...  
 C... G... G...

D F P ( ) 2016

E P T R		A (RMB10,000)	B	
			M D F L	RMB1,500,000 S M T J L S A T J C
F P P	2016F P C	S F F	500	D RMB1,000,000 C A P A 2016. P F F C F A P N F H TB S RMB1,000 A T 1,000 TB
			D	RMB400,000 S C F 2016 S C C R C
	D P IT	H D C	1.5	D 7 H D
B	S M	M	2	S M S M S
		R C H C P C H D T M C S C H T J S S C P J H S C S P T H	30	P D P H O R C
M D &			60	T S B J Q N B T M B H
	D C P	D		
S	F	G	0.5	
T	F	H	4	12
H P	A	R C F C	18.8	H P F C
	F	E	2	F B R C
P	F	7	0.4	8 ( T ( T ( T19-1TT ( ) 5 )32 )0.5 (27 T 1.5 ( )0.5 ( )2)T)7.1 ( )0.5 ( )0.5 ( )0.5 ( ) 805 /TT015(10 -52.1 )0.5(238 1用)23T)04-23 )0.5215( (0.4) )2 0.3.16)6 (5 T )229





# Performance Indicators

		Financial Performance				
		2012	2013	2014	2015	2016
		(RMB/100,000)	(RMB/100,000)			
Net Profit	(RMB/100,000)*	6.05	6.84	7.21	7.86	9.19
Basic Profit	(RMB/100,000)	0.80	0.90	0.92	1.07	1.21

		Financial Performance				(RMB10,000)
		2012	2013	2014	2015	2016
		(RMB10,000)	(RMB10,000)			
Revenue		734,078	999,641	1,202,553	1,260,865	1,462,882
Operating Profit		186,598	214,062	192,501	234,662	212,540
Operating Profit		203,599	281,883	239,435	329,717	339,942
Profit		9,725	10,436	34,047	10,666	19,511
Loss		1,020	1,692	1,676	3,200	2,298
Other		282	1,045	85	362	974
Total		212,304	290,627	271,805	337,183	357,155
Loss		28,376	50,632	34,821	50,117	35,021
Net		183,927	239,995	236,984	287,066	322,134
Net		156,392	202,706	211,287	246,009	280,584
M		27,536	37,289	25,697	41,057	41,550
T		78,900	105,080	126,821	143,449	163,136
D		333	424	735	847	797

Note: We are using the financial data for 2015, the Company's actual performance, and the financial data for 2014, the Company's actual performance, and the financial data for 2016, the Company's actual performance.



# S c a l d c a 1

.....

.....

.....

.....

.....

.....

.....

.....

# Core data

Environmental Health Safety (EHS) Key Performance Indicators

Indicator	2014	2015	2016
Total energy consumption (10,000 kWh)	421,765,752	424,467,622	478,175,186
Energy consumption per unit of production (10,000 kWh)	51,835,011	52,209,518	58,815,548
Total greenhouse gas emissions (10,000 t CO <sub>2</sub> e)	122,713,255	121,204,106	126,874,724
Carbon footprint (10,000 t CO <sub>2</sub> e)	174,548,266	173,413,623	185,690,272
Environmental incidents (RMB10,000)	171	157	126.93
Total environmental incidents (RMB10,000)	8,377,364	8,716,937	8,769,376
Environmental incidents per unit of production (RMB10,000)	8.23	7.89	5.99
Environmental incidents per unit of production (RMB10,000)	3,200	3,166	3,346
Environmental incidents per unit of production (RMB10,000)	1,200	2,156	2,027
Occupational safety incidents (RMB10,000)	2,000	1,010	1,319
Total occupational safety incidents	136,637	871,123	563,081
Total occupational safety incidents	5,677,448	6,285,061	6,785,400
Total occupational safety incidents	50,258	65,597	80,848.14
Total occupational safety incidents	15,757	15,187	16,325
Laboratory safety incidents	N/A	0.424	0.116
Risk management incidents	N/A	0.533	0.21
Occupational safety incidents	14.88%	12.58%	14.89%
Health and safety incidents (RMB10,000)	2,060	4,505	3,155
Total health and safety incidents	N/A	71,474	93,431
Dust emissions (10,000 t)	N/A	4.71	5.75
Energy consumption COD (10,000 t)	440	488	490
Energy consumption NH3-N (10,000 t)	60.94	56.00	60.55
Energy consumption (10,000 t)	90	411	466
Energy consumption (10,000 t)	318	408	485
Energy consumption (10,000 t)	130	110	19

# Feedback F 1

D R ,

T 2016 F P S R R

...

C : S L T : +86 21 33987125

P : P B P R D ( ) B A, C T P , N . 1289 R , S P : 200233

E : @

S F P (G ) C , L . 2016 C S R R F F

N :

E :

R :

T :

E :

F O S :

1H

2H S F P (G ) C , L . ?

3H S F P (G ) C , L . ?

4H S F P (G ) C , L . ?

5H S F P (G ) C , L . ?

## Feedback e 2016 F Para Sa Ca Re

## b Re 1

L Hef , E ec e V ce- C a a a d S e c r e t a r , G e r a f e S a g a F e d e r a l e f E c o n o m i a e O r g a n i z a c a o

T 2016 F P S R R

Z a g H a - E r , F e d e r a l e f R a t o g C S R R a t o g ( R K S )

A F P T T F P F

C e W e b e g , G e r a M a g e r f G d e B e e ( B e g ) M a g e e C e g C , L d .

T 2016 F P S R R

F F P E D N 2030 A S C F D C C F P A C

**Table fC a, Name**

F	S
J B G C, L	B
S C B C, L	C B
H F P C, L	F
S P C L	P
J P C, L	J
S S B	
P C, L	S
J H P C, L	H P
C P C, L	P
S H P C, L	H P
C C P C, L	C P
S S (H) B E C, L	S S
G P C, L	G P
S H P C, L	H P
J A P C, L	A P
D A B C, L	A
H D P C, L	D P
	C
C P R I C, L	R I
S H B C, L	S H
S S T P C, L	S T P
S E P C, L	E P
S G C, L	S
	J C
A J C H	H
G H C, L	G H
S H C, L	H
	C
F C C H C, L	H
	L M
S F L M M S C, L	M
S F B B C, L	F B
B (S) C, L	B

F	S
T C M T C, L	C M
C (B) I T C, L	C (B)
C M L	CML
C I, I	C, CHD
A L L	A
H M I C, L	H M
	S
S T T C, L	T
S L B T E C, L	L T
S F M S C L	F M S
I S, I	I S
S F H T (G) C	F G
L	
S F P C, L	F P
	S
S B, I	B
S F P T	F P
D C, L	
	A
A T I	T
L G	L
A, I	A
C F P R C, L P F	
C R P C, L	R P
C S I T C L C S	
C T I T C L	C T
S F H I (G) C, L	F H I
S, I	S
G E C	GE
H T P C, L	T
G P L	G P

Lined writing area consisting of 24 horizontal dotted lines.

# Ter g e

T	D
GRI	A G R I
FSC	A F S C
EHS	A E ,H S
CAPA	A C A &P A
FDA	A F D A ( S)
HO-PQ	H O PQ Q P PQ. I
TO	A T O AIDS,
GMP	A G M P
GMP	A C G M P
OOS	A O S S
SOP	A S O P
GCP	A G C P
CSR	A C -S -R
A	A
CME	T O M T P G P 2014 P
IT	A I T
NGO	A N -G O
CE	A E C F CE CE
T	T - G E T G
ISO13485	T Q M S M D I O .T
	S (ISO)
	I

S

62-6.303 T (S)-546-S



---

---

---

---

---

---

---

---



# T 1 d Par E a a

D  
PRC  
T  
C  
F P  
C  
F P G  
F P  
M  
EHS  
F  
P  
A  
F P  
A  
A  
C  
F P  
2020  
S D G (SDG) N  
I F P  
F P  
C  
C  
F P  
C B C S D  
Q

## Guidance categories by reference (GB 36002)

S N	C	P
<b>Decoding categories (Z-1)</b>		
-1-1	T	15-17
-1-2	P	3
-1-3	M	17
-1-4	E	23-25, 34-39
-1-5	M	23-25
-1-6	M	24-30
-1-7	M	23, 26-31
-1-8	I	27-31
-1-9	M	24, 100, 105-111
-1-10	M	19-20, 24
-1-11	M	23-25
-1-12	M	19-22
<b>Category (R-1)</b>		
R-1-1	R	13, 41, 55, 80-81, 98, 101
R-1-2	R	99, 104-105
R-1-3	R	N/A
R-1-4	R	38-39
R-1-5	R	98
R-1-6	R	98-99
<b>Category (R-2)</b>		
R-2-1	D	52-53, 104-105
R-2-2	T	38, 104
<b>Category (R-3)</b>		
S N	C	
R-3-1	R	99, 104-105
R-3-2	M	92-100
R-3-3	M	98-99
R-3-4	M	98-99

**G da ce ca f g ca re b y er f a ce (GB 36002)**

S	C	P
N		
<b>E e a d a re a (L-1)</b>		
L-1-1	N	98-99
L-1-2	N	92-99
L-1-3	P	92-99
L-1-4	E	98-99
L-1-5	N	98-99
L-1-6	N	98-99
L-1-7	P	22, 98-99
L-1-8	T	98-99
L-1-9	M	50-51
<b>W r g c d a d ca r ec (L-2)</b>		
L-2-1	T	58-60, 80-84
L-2-2	P	80-84, 100
L-2-3	R	98
L-2-4	M	98-100
L-2-5	D	38-39
L-2-6	E	38-39, 98-99
L-2-7	N	98-99
L-2-8	P	92-100
L-2-9	R	92-100
L-2-10	R	98-100
L-2-11	C	98-99
<b>De g a r g e r a cea dc ec ed c (L-3)</b>		
S	C	
N		
L-3-1	M	99
L-3-2	E	99, 104-105
L-3-3	M	98-99, 104-105
L-3-4	E	98-99, 104-105
L-3-5	T	21-22, 104-105
<b>Occ a a ea a d a fe (L-4)</b>		

**G da ce ca f g ca re b e f a ce (GB 36002)**

S N	C	P
L-4-1	T	58
L-4-2	C	80-81
L-4-3	T	80
L-4-4	C	81
L-4-5	P	83-84
L-4-6	R	81-82
L-4-7	S	81
L-4-8	E	81
L-4-9	M	81
L-4-10	P	86-88
L-4-11	P	89

**De e e a d a g f a e r (L-5)**

L-5-1	P	93-97
L-5-2	M	98-99
L-5-3	P	98-99

**Pre e e f a e (H-1)**

H-1-1	T	58-59
H-1-2	T	71-74
H-1-3	M	71-74
H-1-4	M	71-74
H-1-5	T	71-74
H-1-6	M	71-74
H-1-7	P	75-76
H-1-8	S	75-76
H-1-9	P	60

**T e e f a a b e r a ce (H-2)**

H-2-1	T	60-63
H-2-2	M	60-63
H-2-3	R	64-65
H-2-4	M	64

**G da ce ca f g ca re b e f a ce (GB 36002)**

S	C	P
N		
H-2-5	M	65
H-2-6	M	64-65, 72-73
H-2-7	M	78
H-2-8	P	58-61
H-2-9	M	57-89

**A e a a da a e c a e c a ge (H-3)**

H-3-1	T	79-80
H-3-2	M	79-80
H-3-3	M	79-80
H-3-4	E	60-65
H-3-5	M	(GHG) 79
H-3-6	E	64-65
H-3-7	M	79-80
H-3-8	T	60-61
H-3-9	M	79
H-3-10	M	N S

**E e a e c b d e e a d e e c e f e a a a b a (H-4)**

H-4-1	T	79
H-4-2	T	79
H-4-3	C	79
H-4-4	I	65, 79
H-4-5	M	79
H-4-6	T	61-77
H-4-7	M	N E
H-4-8	T	N A
H-4-9	T	78
H-4-10	E	79

**G da ce ca f g ca re b e r a ce (GB 36002)**

S	C	P
N	M	
H-4-11		79
<b>A c t i v e (G-1)</b>		
G-1-1	T	104-105
G-1-2	T	105
G-1-3	T	105
G-1-4	M	104-105
G-1-5	M	19
G-1-6	E	104-105
G-1-7	T	104-105
G-1-8	T	N E
G-1-9	T	104-105
G-1-10	M	104-105
<b>F a c t o r s (G-2)</b>		
G-2-1	T	48
G-2-2	P	N S
G-2-3	M	48
G-2-4	M	N E
G-2-5	R	98-99
<b>P r o f e s s i o n a l s (G-3)</b>		
G-3-1	T	50
G-3-2	M	50
G-3-3	D	28
G-3-4	M	N S
G-3-5	M	N S
G-3-6	F	50
<b>R e c o m m e n d a t i o n s (G-4)</b>		
G-4-1	T	34
G-4-2	34	



**G da ce ca f g ca re b y e r f a ce (GB 36002)**

S	C	P
N	M	
-3-2		44-46

**C e r e r ce , r a d c a a d d e a d g (X-4)**

	M	
-4-1		47
-4-2	T	47
-4-3	T	N S
-4-4	T	48
-4-5	A	27, 48
-4-6	R	27, 48
-4-7	T	27, 47-48

**C e r l f a s P r e c a d P r a c (X-5)**

-5-1	R	47-48
-5-2	N	47-48
-5-3	L	47-48
-5-4	C	47-48
-5-5	N	47-48
-5-6	M	47-48
-5-7	A	22
-5-8	P	22
-5-9	P	22

**A c s f b a c e r ce (X-6)**

-6-1	I	48
-6-2	P	98
-6-3	T	47
-6-4	M	48
-6-5	F	N E



**G da ce ca f g ca re b y e f r a ce (GB 36002)**

S	C	P
N	S	47, 53
-6-6		
<b>Ed ca a dA are e (X-7)</b>		
-7-1	C	86-88
-7-2	C	48
-7-3	C	48
-7-4	C	27
-7-5	C	27
-7-6	C	N S
-7-7	C	N S
-7-8	C	N S
-7-9	C	27
-7-10	C	N S
<b>S ca Par c a (S-1)</b>		
S-1-1	C	108
S-1-2	F	N E
S-1-3	P	105, 107
S-1-4	M	104-105
S-1-5	I	108
S-1-6	M	108
<b>Ed ca a dC are (S-2)</b>		
S-2-1	F	106
S-2-2	M	106
S-2-3	A	107
S-2-4	P	
S-2-5	A	
<b>E e e e e a d de e e (S-3)</b>		
S-3-1	E	92
S-3-2	T	93-94
S-3-3	M	50
S-3-4	M	92



## G4 ba Re gI a e G4I d ca I de

N.	C	P
<b>G4 GENERAL STANDARD DISCLOSURES</b>		
<b>STRATEG AND ANAL SIS</b>		
G4-1*	C, P (CEO, )	3
G4-2	P	3, 4, 16-17, 139
<b>ORGANIZATIONAL PROFILE</b>		
G4-3*	R	F, C, 11, 13, B, C
G4-4*	R	12, 44
G4-5*	R	B, C
G4-6*	R	12, 18
G4-7*	R	4, 11, 19
G4-8*	R	18, 35-37, 42, 44
G4-9*	R	12
G4-10*	.R NGC	92-93, 99
G4-11*	R	98
G4-12*	D	50, 78
G4-13*	R	14, 27-30, 50
G4-14*	R	46, 104-105
G4-15*	L	29-30
G4-16*	L	31
<b>IDENTIFIED MATERIAL ASPECTS AND BOUNDARIES</b>		
G4-17*	.L .R	4, 116-117
G4-18*	.E .E C	A, B R, P, D, R 23, 117, 139
G4-19*	.L A	23

\*N e: T e ar ed . \* der e GRI4 Ge era S a dard D c re d ca e a e e be g e c . d c re f GRI4 ca d a dard . S be c e e re e e f e c re a dard, a e a e e d ca t a be d c e d f e a c c e a . b a a a e c . der e GRI4 S e c a dard d c re .

## G ba Re 10 gl 1a e G4I d ca 1 I de

N	C	P
G4-20*	F A A B	23
G4-21*	F A A B	23
G4-22*	R	112-113
G4-23*	R S A B	4, 12, 117

### STAKEHOLDER ENGAGEMENT

G4-24*	P	26-30
G4-25*	R	26-30
G4-26*	R	26-30
G4-27*	R	26-30

### REPORT PROFILE

G4-28*	R ( )	4
G4-29*	D ( )	4
G4-30*	R ( )	4
G4-31*	P	115
G4-32*	.R .R GRI C I ( ) .R E A R .R GRI	4, 131-138
G4-33*	.R .I .R .R	4, 121, 140-141

### GOVERNANCE

G4-34*	R	19-20
G4-35	R	19-20
G4-36	R	19-20
G4-37	R	23-25
G4-38	R	19-20
G4-39	R C ( )	19-20
G4-40	R	19-20

N	C	P
G4-41	R	19
G4-42	R	17, 44, 58, 104
G4-43	R	34-39, 56-91, 104
G4-44	.R	19-22
G4-45	.R	3, 19, 27-30
G4-46	R	19-22
G4-47	R	21, 35-38, 104
G4-48	R	19
G4-49	R	19
G4-50	R	19
G4-51	.R	38-39, 59, 98
G4-52	R	19
G4-53	R	



## G ba Re g l a e G4 I d ca r l de

N.	C	P
G4-EC2	F	58-59
G4-EC3	C	39, 98
G4-EC4	F	
<b>Mari e Pre e ce</b>		
G4-EC5	R	39, 90
G4-EC6	P	92-93
<b>I d r ec Ec c l ac</b>		
G4-EC7	D	105-107
G4-EC8	S	34-35
<b>Pr c r e e Pr ac ce</b>		
G4-EC9	P	46-48

## ENVIRONMENTAL

<b>Mari a</b>		
G4-EN1	M B O	50
G4-EN2	P O M T A R I M	61-69
<b>E erg</b>		
G4-EN3	E C T O	65-74
G4-EN4	E C O O T O	N S
G4-EN5	E I	61
G4-EN6	R O E C	64-65
G4-EN7	R I E R O P A S	64
<b>Wate</b>		
G4-EN8	T B S	61
G4-EN9	S S A B O	N S E
G4-EN10	P A T O R A R	65
<b>B d er</b>		
G4-EN11	O S O , L , M I , O A T , P A A A O H B O P A	N S E
G4-EN12	D O S I O A , P , A S O B I P A A A O H B O P A	N S E
G4-EN13	H P O R	N S E
G4-EN14	T N I C N R L S A N C L S H I A A B O , B L O E R	N S E

N	C	P
<b>E</b>		
G4-EN15	D. G (G )E (S 1)	79
G4-EN16	E I G (G )E (S 2)	79
G4-EN17	O I G (G )E (S 3)	62,79
G4-EN18	G ( )	N S
G4-EN19	R ( )	N S
G4-EN20	E ( )	N S
G4-EN21	N	71
<b>E e a dWa e</b>		
G4-EN22	T	72
G4-EN23	T	75-76
G4-EN24	T	N S E
G4-EN25	B C I, II, III III,	N S E
G4-EN26	I	N S E
<b>P d c a dSer ce</b>		
G4-EN27	E	60
G4-EN28	P	66-70
<b>C a ce</b>		



## Global Impact G4 Indicators

Indicator	Category	Page
<b>LABOR PRACTICES AND DECENT WORK</b>		
<b>Employee</b>		
G4-LA1	Total number of employees	93, 99
G4-LA2	Board diversity	38-39, 98
G4-LA3	Retention rate	98
<b>Labor/Management Relations</b>		
G4-LA4	Materiality of labor relations	98
<b>Occupational Health and Safety</b>		
G4-LA5	Prevalence of occupational health and safety incidents	83-84
G4-LA6	Total number of occupational health and safety incidents	80-83
G4-LA7	Lost time due to occupational health and safety incidents	83-84
G4-LA8	Hours worked by employees	86-88
<b>Training and Education</b>		
G4-LA9	Hours of training and education	95
G4-LA10	Percentage of employees with training and education	93-97
G4-LA11	Percentage of employees with training and education	98
<b>Derivatives and Other Financial Instruments</b>		
G4-LA12	Contractual notional amounts	93
<b>Executive Remuneration and Compensation</b>		
G4-LA13	Remuneration of executive directors	38-39, 98
<b>Senior Management of Labor Practices</b>		
G4-LA14	Percentage of senior management with labor practices training	N/A
G4-LA15	Senior management with labor practices training	N/A, E
<b>Labor Practices Governance Mechanisms</b>		
G4-LA16	Number of labor practices governance mechanisms	98
<b>HUMAN RIGHTS</b>		
<b>Incidents</b>		
G4-HR1	Total number of human rights incidents	N/A
G4-HR2	Total number of human rights incidents	93-97





## Governance and Compliance

N.	C	P
<b>Accountability</b>		
G4-SO7	T	N S... E
<b>Compliance</b>		
G4-SO8	M	N S... E
<b>Senior Management and Staff Safety</b>		
G4-SO9	P	N S...
G4-SO10	S	50,78
<b>Grease Mechanical Safety</b>		
G4-SO11	N	N S... E

## PRODUCT RESPONSIBILITY

<b>Consumer Health and Safety</b>		
G4-PR1	P	N S...
G4-PR2	T	N S... E
<b>Product and Service Labeling</b>		
G4-PR3	T	44-46, 48
G4-PR4	T	N S... E
G4-PR5	R	27, 31, 53
<b>Marketing Communications</b>		
G4-PR6	S	N S... E
G4-PR7	T	N S... E
<b>Consumer Privacy</b>		
G4-PR8	T	N S... E
<b>Compliance</b>		
G4-PR9	M	N S... E




I A S 12- 50 F P D  
 F P RMB300,000 S  
 I A H A  
 L H F P  
 T H I

# Assurance Statement of SGS



## ASSURANCE STATEMENT

SGS-CSTC STANDARDS TECHNICAL SERVICES CO., LTD. SHANGHAI



# Assurance Statement of SGS

The assurance team was assembled based on their knowledge, experience and qualifications for this assignment, and comprised auditors registered with Sustainability Reporting Assuror, SAI

auditor, CGA#19014001 Lead Auditor, CGA#0959318001 Lead Auditor, and pharmaceutical industry experts etc.

Registered SA#6002 Lead Auditor, and pharmaceutical

## ASSURANCE OPINION

On the basis of the methodology described and the verification work performed, we are satisfied that the information and data reported within 2016 CSR Report verified is accurate, reliable and

On the basis of the methodology described and the verification work performed, we are satisfied that the information and data reported within 2016 CSR Report verified is accurate, reliable and

provides a fair and balanced representation of FOSUNPHARMA's sustainability activities and relevant performance in 2016. The assurance team is of the opinion that the Report can be used by the Reporting Organization's Stakeholders.

In our opinion, FOSUNPHARMA has chosen an appropriate option of assurance for this reporting.

their reporting

## REPORTING INITIATIVE REPORTING GUIDELINES (2013) CONCLUSIONS FINDINGS AND RECOMMENDATIONS

## GLOBAL FINDINGS

### Stakeholder Inclusiveness

FOSUNPHARMA had effectively identified the stakeholder. Established the channel and platform for stakeholder's communication and inclusiveness and took different ways to communication and exchange information.

Stakeholder inclusiveness FOSUNPHARMA stakeholder exchange

### Sustainability Context

FOSUNPHARMA had presented the context of its operations in the areas of environmental, social, and economic, environmental and social conditions and combined the performance in the wide context.

### Sustainability Context

### Materiality

FOSUNPHARMA had presented the context of its operations in the areas of environmental, social, and economic, environmental and social conditions and combined the performance in the wide context. reflect the organization's significant economic, environmental and social impact or substantive influencing the assessments and decisions of stakeholders. SGS recommended that FOSUNPHARMA should strengthen involvement much more materiality topics and indicators internal Enterprises' management

### Completeness

FOSUNPHARMA's report included coverage of material aspects and boundaries significant economic, environmental and social impacts, to enable stakeholders organization's performance in the reporting period. SGS recommended that the organization should include the coverage of external entities with significant impacts while collected information.

### Balance

FOSUNPHARMA's report complied with the balance principle with both positive and negative information. SGS recommended that the organization could describe in detail how to take measures.

### Comparability

FOSUNPHARMA's report disclosed the performance year by year, and against other organizations (or on a global level). SGS recommended that the organization should disclose, which could help stakeholders to understand the performance. SGS recommended that the organization should collect data in the same field, such as pharmaceutical, hospital performance

# Assurance Statement of SGS

## Accuracy

FOSUNPHARMA's information in the report was accurate, capable to reveal more qualitative and quantitative information for stakeholders.

## Timeliness

Assurance to know that the data and information was on a regular schedule and available in time. FOSUNPHARMA will report on a regular schedule with one year to assure the good timeliness.

## Clarity

Report was presented different ways with words, charts, graphics and pictures, also describe with actual cases as well to ensure the stakeholders understanding easily. SGS recommended that same approach in the report can be applied on length documents.

ording=analyzing and disclosing methods-managing-and  
ation was reliable. SGS recommended that data of  
s of the data

Technical Services Co., Ltd. Shanghai Branch

Shanghai, China

## Reliability

Through information and data collecting, recording in CSR report, the data and information energy saving project do not use the estimate

## Signed:

For and on behalf of SGS CSTC Standards



Ben Tsang  
Director, China and Hong Kong  
Certification and Business Enhancement  
28-Mar 2017--

B#11/F, No.900, Yishan Road, Xuhui District,  
[WWW.CN.SGS.COM](http://WWW.CN.SGS.COM)



# **FOSUNPHARMA**



Follow us on WeChat

Shanghai Fosun Pharmaceutical (Group) Co., Ltd.

Building A, Fosun Hi-Tech Park, No.1289 Yishan Road, Xuhui District, Shanghai, P.R. China, 200233

Tel: +86 21 3398 7000

Fax: +86 21 33987020

For more information, please visit [www.fosunpharma.com](http://www.fosunpharma.com)